JP2011520808A - 正常細胞の保護 - Google Patents

正常細胞の保護 Download PDF

Info

Publication number
JP2011520808A
JP2011520808A JP2011508574A JP2011508574A JP2011520808A JP 2011520808 A JP2011520808 A JP 2011520808A JP 2011508574 A JP2011508574 A JP 2011508574A JP 2011508574 A JP2011508574 A JP 2011508574A JP 2011520808 A JP2011520808 A JP 2011520808A
Authority
JP
Japan
Prior art keywords
sulindac
epimer
derivatives
composition
damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011508574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520808A5 (enExample
Inventor
ワイスバハ，ハーバート
ブロト，ネイサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Florida Atlantic University
Original Assignee
Florida Atlantic University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florida Atlantic University filed Critical Florida Atlantic University
Publication of JP2011520808A publication Critical patent/JP2011520808A/ja
Publication of JP2011520808A5 publication Critical patent/JP2011520808A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011508574A 2008-05-05 2009-05-04 正常細胞の保護 Pending JP2011520808A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/115,331 2008-05-05
US12/115,331 US8487128B2 (en) 2002-11-26 2008-05-05 Protection of normal cells
PCT/US2009/042703 WO2009137400A2 (en) 2008-05-05 2009-05-04 Protection of normal cells

Publications (2)

Publication Number Publication Date
JP2011520808A true JP2011520808A (ja) 2011-07-21
JP2011520808A5 JP2011520808A5 (enExample) 2012-06-21

Family

ID=41265328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508574A Pending JP2011520808A (ja) 2008-05-05 2009-05-04 正常細胞の保護

Country Status (7)

Country Link
US (2) US8487128B2 (enExample)
EP (1) EP2282733A4 (enExample)
JP (1) JP2011520808A (enExample)
CN (1) CN102112124A (enExample)
AU (1) AU2009244500A1 (enExample)
CA (1) CA2755499A1 (enExample)
WO (1) WO2009137400A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513136A (ja) * 2013-02-28 2016-05-12 アニダ ファーマ インコーポレイテッド 聴器毒性を治療する方法
JP2017178920A (ja) * 2015-12-25 2017-10-05 共栄化学工業株式会社 皮膚外用組成物及び経口組成物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487128B2 (en) * 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
CA2696627C (en) 2007-08-17 2016-09-27 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2882426A1 (en) * 2012-08-13 2015-06-17 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for treatment of cystic fibrosis
KR102354613B1 (ko) 2012-11-15 2022-01-21 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
WO2014160702A1 (en) 2013-03-25 2014-10-02 Chs Pharma, Inc. Retinopathy treatment
HUE066137T2 (hu) 2013-10-18 2024-07-28 Novartis Ag A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére
JP6464166B2 (ja) 2013-11-14 2019-02-06 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 陽電子放出断層撮影用の化合物
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US11186534B2 (en) * 2017-03-17 2021-11-30 University Of South Alabama Derivatives of sulindac can protect normal cells against oxidative damage
PL237474B1 (pl) * 2017-05-04 2021-04-19 Wyzsza Szkola Medyczna W Bialymstoku Nowe zastosowanie kwasu 2-[(3Z)-6-fluoro-2-metylo-3-[(4-metylosulfinylofenylo) metylideno]inden-1-ylo] octowego
CA3097381A1 (en) 2018-04-17 2019-10-24 Endocyte, Inc. Methods of treating cancer
CN120097930A (zh) 2019-05-20 2025-06-06 因多塞特股份有限公司 制备psma缀合物的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047772A2 (en) * 2002-11-26 2004-06-10 Florida Atlantic University Catalytic antioxidants and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053429A (en) 1988-04-08 1991-10-01 The Lithox Corporation, Inc. Treating inflammatory pain with methionine
US5401774A (en) * 1991-03-08 1995-03-28 University Of Arizona Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
US5608067A (en) 1993-12-09 1997-03-04 Afonso; Adriano 4-substituted pyrazoloquinoline derivatives
US6201028B1 (en) * 1998-12-08 2001-03-13 The Rockefeller University Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs
EP1469884A1 (en) * 2002-01-30 2004-10-27 Pharmacia Corporation Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
US8487128B2 (en) * 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
WO2007130575A2 (en) 2006-05-03 2007-11-15 Florida Atlantic University Protection against oxidative damage in cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047772A2 (en) * 2002-11-26 2004-06-10 Florida Atlantic University Catalytic antioxidants and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013044096; ＣＩＲＣＵＬＡＴＩＯＮ ＶＯＬ．１１０，　ＮＯ．１７，　ＳＵＰＰＬ．, 2004, Ｐ．１８９，９００ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513136A (ja) * 2013-02-28 2016-05-12 アニダ ファーマ インコーポレイテッド 聴器毒性を治療する方法
JP2017178920A (ja) * 2015-12-25 2017-10-05 共栄化学工業株式会社 皮膚外用組成物及び経口組成物

Also Published As

Publication number Publication date
US8871971B2 (en) 2014-10-28
EP2282733A2 (en) 2011-02-16
US20090326073A1 (en) 2009-12-31
US20140018429A1 (en) 2014-01-16
CN102112124A (zh) 2011-06-29
CA2755499A1 (en) 2009-11-12
AU2009244500A1 (en) 2009-11-12
EP2282733A4 (en) 2012-12-12
US8487128B2 (en) 2013-07-16
WO2009137400A2 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
JP2011520808A (ja) 正常細胞の保護
US20090069428A1 (en) Catalytic antioxidants and methods of use
US20180050989A1 (en) Aldehyde trapping compounds and uses thereof
JP2008538586A (ja) 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド）
JP2005525345A (ja) Ｔｒｘ媒介性疾患を処置する方法
JP2013525375A (ja) 金属酵素阻害化合物
BR112014026551B1 (pt) uso de um composto para inibir uma oxidase alternativa (aox)
JP2001505209A (ja) ヒドロキシグアニジン類の使用
JP2024015132A (ja) Ｏ－環状フィトスフィンゴシン－１－フォスフェートを含むパーキンソン病の予防又は治療用組成物
US11273135B2 (en) Methods for using stabilized sulforaphene
US10137102B2 (en) Oligomeric forms of 3-hydroxybutyrate
JP4109123B2 (ja) ペプチドデホルミラーゼ活性化プロドラッグ
Mason et al. A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids
TW201717959A (zh) 用於對金屬卟啉進行微粒遞送之調配物及用途
JP2020019734A (ja) 脳梗塞の処置用の医薬組成物
US11723907B2 (en) Anti-aging compounds
WO2017060400A1 (en) Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
US20140142189A1 (en) Methionine analogs and methods of using same
JP2015160847A (ja) 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN114181225B (zh) 一种含笑内酯衍生物及其药物组合物、制备方法和用途
JP2009040688A (ja) メラニン生成抑制剤
CN102488692B (zh) 乙酰乳酸合成酶抑制剂化合物作为制备抗真菌药物的应用
CN119454719A (zh) 雷公藤红素作为结核分枝杆菌乙酰羟基酸合酶先导抑制剂的应用
JP3435741B2 (ja) 新規物質及び該物質を生産する微生物
WO2021188296A1 (en) Methods of treating xanthine oxidase-related diseases with niflumic acid and derivatives thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120507

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140430